Seagen goes to Pfizer for $43B; Sanofi buys diabetes partner Provention; Crisis averted in SVB demise; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
M&A Monday made a major comeback this week and quickly topped the charts as the most-read story. Don’t miss all the other reporting from Endpoints getting into the weeds of other interesting news.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.